
A Johns Hopkins infectious disease expert will lead two international studies of the effectiveness of the antibiotic moxifloxacin as a new treatment for tuberculosis, the highly contagious bacterial disease that kills more than 2 million people worldwide each year and is the leading cause of death of people living with HIV and AIDS.  Moxifloxacin is currently approved in more than 100 countries, including the United States, as a treatment for bacterial respiratory infections, such as bronchitis, sinusitis and pneumonia.  

